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ABSTRACT: Preventing HIV transmission by the use of a
vaginal microbicide is a topic of considerable interest in the
ﬁght against AIDS. Both a potent anti-HIV agent and an
eﬃcient formulation are required to develop a successful
microbicide. In this regard, molecules able to inhibit the HIV
replication before the integration of the viral DNA into the
genetic material of the host cells, such as entry inhibitors or
reverse transcriptase inhibitors (RTIs), are ideal candidates for
prevention purpose. Among RTIs, S- and N-dihydro-
alkyloxybenzyloxopyrimidines (S-DABOs and N-DABOs) are
interesting compounds active at nanomolar concentration
against wild type of RT and with a very interesting activity
against RT mutations. Herein, novel N-DABOs were synthesized and tested as anti-HIV agents. Furthermore, their mode of
binding was studied by molecular modeling. At the same time, a vaginal microbicide gel formulation was developed and tested for
one of the most promising candidates.
■ INTRODUCTION
Since its discovery in 1981, human immunodeﬁciency virus
(HIV) infection continues to be a major health threat
worldwide. Combination antiretroviral therapy (cART) can
signiﬁcantly reduce the viral load and prolong patients’ life
expectancy, but it is not able to totally eradicate the virus.1
Furthermore, the emergence of resistant strains continues to
limit the eﬃcacy of current drugs.2 Accordingly, a great variety
of chemotherapy agents were developed against HIV-1 in the
past 20 years. Most of the anti-HIV studied small-molecules
target the viral enzyme reverse transcriptase (RT) by binding
the polymerase active site (nucleoside RT inhibitors) or an
allosteric pocket (non-nucleoside RT inhibitors or NNRTIs).3,4
More than 30 diﬀerent molecular structures of NNRTIs were
developed, comprising nevirapine, delavirdine, efavirenz,
rilpivirine, and etravirine FDA-approved drugs. Among
NNRTIs, S- and N-dihydroalkylthiobenzyloxopyrimidines (S-
DABOs and N-DABOs) have been extensively modiﬁed by our
research group with the aim of improving their inhibitory
activity toward RT wild-type and clinically relevant mu-
tants.5−13 Several compounds showed nanomolar inhibitory
potency against wild-type HIV-1 and relevant drug-resistant
mutants. Furthermore, previous studies revealed that the
conversion of the S-DABO derivatives into the corresponding
N-DABOs may lead to new derivatives characterized by
improved ADME proﬁles, especially aqueous solubility (Chart
1).13 On the other hand, HIV transmission remains high in
developing countries, and with a vaccine not yet in sight, the
development of an eﬀective prevention strategy would be
desirable. Topical microbicides are preparations able to prevent
the transmission of HIV when applied to the genital and/or
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lower gastrointestinal graft via the rectum.14 It is generally
accepted that a microbicide should act prior to the integration
of proviral DNA into the host cell DNA. Accordingly, the two
main compound classes that could be used to such a purpose
are entry inhibitors and RT inhibitors. Examples of RT
inhibitors in preclinical and clinical evaluation as microbicides
include tenofovir, dapivirine, MIV150, UC781, UAMC01398,
and DABO.15−20 Microbicide candidates must have a good
selectivity index (SI), inhibit virus replication at low, nontoxic
concentrations in vitro, have a good resistance proﬁle, be stable,
and have the potential for reasonable pricing.21−24 In this
context, the purpose of this work was to initiate a study on N-
DABO NNRTIs in order to investigate their potential for the
development of new microbicides. To this aim, a novel series of
N-DABO derivatives was synthesized. Biological evaluation
showed that these compounds are able to inhibit HIV-1
replication at nanomolar concentration. Remarkably, the most
promising derivative in terms of activity against mutant strains,
25e, was also characterized by a high selectivity index, 5-fold
higher than dapivirine, a good cell permeability, and stability
higher than 95%. On this basis, a vaginal microbicide gel
formulation of 25e was developed and evaluated in vitro.
Moreover, in the present work we also reported the
development of a predictive QSAR model for a large set of
S-DABO/N-DABO derivatives.
■ RESULTS AND DISCUSSION
Chemistry. The new compounds were synthesized using
the classical approach for the synthesis of N-DABO, based on
the nucleophilic displacement of the methylsulfonyl group at
C2 position with the appropriate amine. According to Scheme
1, the key intermediates 13 and 14 were synthesized starting
from the appropriate carboxylic acids (3 and 4) that were
methylated with MeI using LDA as a base to obtain compounds
5 and 6 in good yields, while compound 12 was synthesized
directly from acid 4.
The β-ketoesters 9−11 were prepared by activation of acids
4−6 using 1,1′-carbonyldiimidazole (CDI), followed by
treatment with potassium monoethyl malonate 8 in the
presence of anhydrous MgCl2 and Et3N. Then condensation
of 9−11 with thiourea in the presence of EtONa led to
substituted thiouracils 12−14. Subsequent alkylation with MeI
in DMF gave compounds 15−17 in excellent yield. C2-
methylthio group of thiouracils 15−17 was then converted in
the corresponding sulfone derivatives 18−20, by oxidation.
Secondary amines 22b−g were synthesized by reductive
amination of the appropriate aldehyde (21b−g) with methyl-
amine and sodiumborohydride. Nucleophilic substitution of the
C2-methylsulfonyl group of 18−20 with the appropriate amine
led to ﬁnal compounds 23a−f, 24a, 24c−f, and 25d−g
(Scheme 2). Boc deprotection of compounds 23b and 24b led
to compounds 23a and 24a (Scheme 3).
Aldehydes 21b−d were not commercially available and were
synthesized by nucleophilic displacement of the 4-ﬂuoroben-
zaldehyde with the appropriate amine (Scheme 4).
Biology. Antiviral Activity against HIV-1 and Cytotox-
icity. Compounds 23a−f, 24a, 24c−f, and 25d−g were
Chart 1. Hit Compounds Belonging to S-DABO and N-
DABO Families
Scheme 1a
aReagents and conditions: (a) LDA, HMPA, CH3I, dry THF, −78 °C to rt, 12 h; (b) KOH, dry EtOH, 0 °C to rt, 12 h; (c) carbonyldiimidazole,
MgCl2, TEA, dry CH3CN, rt, 12 h; (d) Na
0, thiourea, dry EtOH, reﬂux, 12 h; (e) CH3I, KOH, EtOH, rt, 1 h; (f) m-CPBA, dry DCM, 0 °C to rt, 12
h.
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evaluated for their anti-HIV-1 activity and cytotoxicity in TZM-
bl cells in comparison with TMC120 (dapivirine). The results,
expressed as EC50 (50% eﬀective concentration), CC50 (50%
cytotoxic concentration), and SI (selectivity index given by the
CC50/EC50 ratio) values are summarized in Table 1. Among the
novel N-DABOs, compounds 23e, 23f, 24e, 24d, 25d, 25e, and
25f retained an activity similar to that of the lead 1 and showed
very potent inhibitory activities against the replication of the
V106A25 mutant virus which is resistant to nevirapine (Table
2). On the other hand, the compounds were also active at
nanomolar concentration against V90I, V106A, E138K, and
K101E mutants while modestly active against the L100I,
K103N, and Y181C25 mutants. Moderate activities against WT
RT were found for derivatives 23d, 24a, and 24c. Remarkably,
the most active compounds also showed low cytotoxicity and
resulting high selectivity indices, with the best compound, 25e,
characterized by SI higher than 10 000. This feature together
with the good activity proﬁle makes this compound suitable for
microbicide formulation.
Antireverse Transcriptase Activity. Compounds 23c,
23e, 23f, and 24e were further evaluated for antireverse
transcriptase activity in comparison with nevirapine in an
enzymatic recombinant HIV-1 RT activity assay, and results
expressed as IC50 were compared with anti-HIV-1 activity.
Comparable activity values were found, conﬁrming that the
target of these antiviral agents is the RT and that compounds
are able to permeate through the cellular membrane, inhibit
RT, and subsequently block the HIV-1 replication.
Antiviral Activity for 25e Gel. Antiviral activity testing
was performed with a gel formulation of 25e in direct
comparison with the free drug and the blank gel. As measured
in TZM-bl cells, the EC50 values of formulated and native 25e
are similar, which indicates that formulating 25e does not alter
the in vitro potency of the compound (Figure 1a). In addition,
no loss in antiviral activity was observed for the 25e gel
formulation after storage for 1 month at room temperature and
without light exposure.
To exclude the eﬀect of β-cyclodextrins on the observed
antiviral activity and the toxicity of these gels in vitro even at
low gel concentrations (toxicity was observed at 5% gel
concentration), gels were reformulated without β-cyclodextrins.
Moreover, to reproduce more physiological conditions, TZM-bl
cells were seeded into Transwells and the gel was applied onto
the cell monolayer at 50% ﬁxed concentration with serial drug
(25e or tenofovir) dilutions. This experiment conﬁrmed the
high antiviral activity of 25e gel (EC50 = 30 nM) also in
comparison with the observed eﬃcacy of tenofovir gel (EC50 =
3 μM) (Figure 1b).
In Vitro ADME Studies. Selected N-DABOs were proﬁled
in vitro for aqueous solubility at pH 4.2 and 7.4, liver
microsomal stability, and membrane permeability (Table 3).
Their aqueous solubility (−log S ranging from −6.51 to −8.60
and from −5.49 to −7.99 at pH 7.4 and 4.2, respectively),
although improved over the S-DABOs previously developed,
was rather low. This aspect does not prevent the eﬃcacy of the
gel formulation which is composed of cyclodextrins, commonly
used to increase drug solubility.26,27 Furthermore, cyclodextrins
have been shown to determine a dose-dependent inactivation
of the virus by the removal of cholesterol from the membrane
of HIV-infected cells, thus enhancing the infection prevention
of the microbicide formulation. On the other hand, passive
membrane permeability in a PAMPA assay indicated acceptable
cell permeability values for compound 25e (5.54 and 3.78 ×
10−6 cm/s, at pH 4.2 and 7.4, respectively). Moreover, stability
tests disclosed that all analogues showed excellent metabolic
stability in liver microsomes (∼99%).
Stability of 25e Gel Formulation. 25e gel (85% of
compound was loaded that corresponded with a ﬁnal
concentration of 17 μM) at pH 4.2 (vaginal formulation) was
found to be stable at room temperature without light exposure:
the 25e recovery after 1 month of storage amounted to about
100%. In addition, the viscosity and pH of this gel remained
stable during storage.
Molecular Modeling. Docking Studies. Docking studies
have been previously used to characterize the binding mode of
S-DABOs within the non-nucleoside binding pocket of RT wild
type.11,12 A schematic representation of the main interactions
Scheme 2a
aReagents and conditions: (a) MeNH2, NaHCO3, MeOH, reﬂux 4 h; (b) NaBH4, 0 °C to rt, 1 h; (c) dry toluene, reﬂux, 48 h.
Scheme 3a
aReagents and conditions: (a) 10% TFA in dry DCM, rt 1 h.
Scheme 4a
aReagents and conditions: (a) di-tert-butyl dicarbonate, MeOH,
microwave, 2 min; (b) 4-ﬂuorobenzaldehyde, K2CO3, dry DMF, 130
°C, 12 h.
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established by S-DABOs is reported in Figure 2. Two hydrogen
bonds were detected between the amide moiety of the
pyrimidinone ring and the backbone of Lys101. The C6-benzyl
group established hydrophobic interactions with the aromatic
cage formed by Tyr181, Tyr188, Phe227, Trp229, and Leu100,
while the C6′-group interacted with Val179. Finally proﬁtable
lipophilic interactions were found between the S side chain and
a solvent-exposed channel lined by residues Val106, Pro225,
Tyr318, Phe227, and Pro236.
Herein, molecular docking simulations were conducted on
new N-DABOs following the computational protocol pre-
viously adopted on S-DABOs. Besides Autodock,28 two more
software programs were used, namely, Gold29 and Glide,30,31
and the three computational procedures were extended to a
large set of compounds including 168 S-DABOs/N-
DABOs11−13,32,33 characterized by IC50 values ranging from
0.0003 and 50 μM against RT wt (Table S1, Supporting
Information). In parallel, the same docking analyses were
conducted by considering a well-ordered water molecule
crystallized into the binding pocket of 1RT2 crystal structure,
which forms a triad of hydrogen bonds involving the inhibitor,
the main chain nitrogen of Lys101, and a carboxyl oxygen of
Table 1. Antienzymatic Activity, Antiviral Activity, and Cytotoxicity of the New N-DABO Derivatives
aData represent the mean of at least two experiments. bND: not determined.
Table 2. Anti-HIV Activities of Selected Compounds against Mutant Strainsa
compd EC50 (nM) pNL4.3 WT V90I (nM) L100I (nM) E138 K (nM) K101E (nM) K103N (nM) V106A (nM) Y181C (nM)
23d 100 ND ND 274 >1000 792 18 704
23e 15 ND ND ND ND ND 10 680
23f 8.6 13 220 35 51 367 ND 201
24c 96 ND ND 256 942 1502 15 1288
24d 29 ND ND 103 294 1039 6.3 627
24e 12 ND ND ND ND ND 10 209
25d 7.9 22 1570 42 138 2460 ND 331
25e 5 8.7 84 17 31 102 ND 80
25f 10 30 1498 65 134 518 ND 814
25g 329 687 >10000 950 >10000 >10000 ND >10000
1 93 ND ND 246 450 549 56 1608
2 3 ND ND 9.1 17 34 0.87 94
aAll these viruses are site-directed mutants. pNL4.3 replication competent viruses with single point mutations introduced in HIV RT by site-directed
mutagenesis.
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Glu138 in the p51 chain. Remarkably, the three software
programs converged to the same solution in both the presence
and absence of the water molecule and the poses obtained for
N-DABOs perfectly overlapped with those of S-DABOs
derivatives previously reported. As an example, Figure 3
shows the binding mode of compound 24e aligned with the
congeneric S-DABO.
Although coincident poses were obtained through the use of
diﬀerent docking procedures which made the results highly
conﬁdent, no correlation was found between the scoring
functions employed (Glide SP and XP, Autodock, ChemScore)
and the experimental activity values. Bad results were also
obtained through pose rescoring by X-Score34 (an empirical
Figure 1. Anti-HIV activity of 25e (black line) and 25e gel (red line) in human Tzm-Bl. (a) The EC50 values for the free drug and the gel
formulation were similar, ranging from 2.3 to 3.3 nM, respectively. Each concentration was evaluated in triplicate. Toxicity was evaluated in parallel,
and the blank gel showed toxicity at a concentration higher than 100 nM. (b) The EC50 was evaluated by Transwell assays and without β-
cyclodextrins in the gel formulation. The usage of Transwells has allowed use of the gels at a 50% ﬁxed concentration at all dug dilutions with no
toxicity on the cells. Tenofovir was used as control.
Table 3. In Vitro ADME Proﬁle of N-DADO Derivatives
compd
PAMPA,
pH 7.4
(10−6 cm/s)
PAMPA,
pH 4.2
(10−6 cm/s)
water
solubility,
pH 7.4
(log S)a
water
solubility,
pH 4.2
(log S)a
metabolic
stability
(%)b
23c 21.9 ND −8.6 −7.80 99
23d 1.37 0.58 −6.51 −5.49 99
24d 0.91 ND −8.7 −7.85 99
23f 10.93 1.90 −7.55 −6.70 99
25e 5.54 3.78 −8.60 −7.99 99
alog S = log mol L−1. bExpressed as percentage of unmodiﬁed parent
drug.
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scoring function) and MM-GBSA35 (a force ﬁeld based
function) methods. This was not surprising and was also
recently found for another family of NNRTIs.36 In order to
derive a quantitavive structure−activity relationship, the new N-
DABO derivatives together with additional N-DABOs and S-
DABOs previously described by us11,13 and other research
groups32,33 were submitted to a multiple linear regression
(MLR) analysis with the aim of identifying the molecular
determinants able to inﬂuence their activity against wild type
HIV-1. For this purpose, the MLR algorithm implemented in
Canvas was applied. In particular, 68 compounds with activity
data spanning over 6 orders of magnitude were used as learning
set. Several models were generated by using the cellular data
(EC50) as the independent variable, 87 descriptors as
dependent variables, and choosing in turn an increasing
number of X variables as best subset. Besides the parameters
coming from docking studies, 2D ﬁngerprint descriptors and
QikProp properties were calculated. The learning set (the ﬁrst
68 compounds in Table 1S) was randomly divided into a
training set (80%) and a test set (20%). A good predictive
ability, both internal and external, was found with an equation
characterized by seven descriptors: evdw (van der Waals energy
calculated by Glide during the docking with water), PISA (π,
carbon, and attached hydrogen, component of the SASA), three
prime descriptors37,38 (prime mmgbsa bind lipo, prime mmgbsa
DG bind, primesolv GB), HPScore,34 dendritic (2D ﬁnger-
print).39 Equation was assessed by both internal and external
validation procedures. Good r2 (0.76) and leave-three-out
cross-validated correlation coeﬃcients q2 (0.72) were found
(Figure 4). We decided to stop our analysis to seven properties
because increasing the number of descriptors, even to
determine an improvement of the predictive power of the
model on the training set, led to bad q2 values on the external
test set. Remarkably, the 68 compounds belonging to the
learning set were extracted from the larger original database of
168 derivatives on the basis of a solubility criteria (QPLogS <
−6.0). Indeed, because of their scarce solubility, some
Figure 2. Binding mode of S-DABOs within the NNBP of RT wt
(PDB code 1RT2) as previously predicted by docking studies through
the Autodock software.
Figure 3. Binding mode of compound 24e (sky blue stick) within the
NNBP of RT. For comparison purposes, the congeneric S-DABO
(gray stick) is also visualized. For the sake of clarity, only a few key
residues are labeled, hydrogen atoms are omitted, and hydrogen-
bonding interactions are represented by black dashed lines.
Figure 4. Experimental activity (−log EC50) versus predicted activity (Pred −log(EC50)) in the ﬁnal MLR model. Red points represent prediction
for the training set, while blue points represent predictions for the test set.
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derivatives tended to precipitate from medium, and their
activity values were thus underestimated. Accordingly, the
models generated including all compounds were characterized
by lower r2 values (r2 < 0.5, data not shown). Overall, this study
suggests that docking scoring functions are poor in predicting
the activity of DABO derivatives against RT. However, a
regression model combining docking results with other 2D
descriptors gives the possibility to obtain more accurate
prediction. The model generated herein could be exploited
for the design of new S-DABO/N-DABO RT inhibitors taking
into due consideration that the application domain of this
QSAR model is limited to compounds with QPLogS < −6.0.
■ CONCLUSIONS
N-DABOs, which previously appeared to be very potent against
HIV-1 with a good activity against NNRTI-resistant viruses,
also proved to have an excellent cellular safety proﬁle and to
possess pharmacokinetic characteristics that make them
promising microbicide gels to be used for HIV prevention.
This family of RT inhibitors was further explored herein by the
synthesis and biological evaluation of new derivatives. Among
them, 25e was chosen to be formulated because of its good
activity proﬁle and high selectivity index (>17 000), an
important feature for the development of an eﬀective topical
microbicide. The gel formulation has been shown to be stable
and eﬀective against HIV-1 replication. Remarkably, 25e
formulated in gel form demonstrated ability in treating HIV-1
infection comparable to that of the free drug. Overall, results
reported herein support the anti-HIV microbicide potential of
N-DABO RT inhibitors.
■ EXPERIMENTAL SECTION
Methods. All commercially available chemicals were used as
purchased. DCM and CH3CN were dried over sodium hydride. EtOH
was dried over Mg. THF and toluene solvents were dried over Na/
benzophenone prior to use. Anhydrous DMF was used as purchased.
Anhydrous reactions were run under a positive pressure of dry N2 or
Ar.
Instrumentation. 1H NMR and 13C NMR spectra were measured
on a 400 and 100 MHz spectrometer, respectively. Chemical shifts for
protons are reported in parts per million (δ scale) and internally
referenced to the CDCl3 signal at δ 7.24 ppm, to the DMSO at δ 2.50
ppm, and to the D2O signal at δ 4.79 ppm. Chemical shifts for carbon
are reported in parts per million (δ scale) and referenced to the carbon
resonances of the solvent (CDCl3: δ 77.76 ppm, the middle peak).
Data are presented as follows: chemical shift, multiplicity (s = singlet, d
= doublet, dd = double doublet, td = triple doublet, t = triplet, q =
quartet, m = multiplet and/or multiplet resonances, br = broad),
coupling constant in hertz (Hz), and integration. The purity of
compounds was assessed by reverse phase liquid chromatography and
a mass spectrometer with a UV detector at λ= 254 nm and an
electrospray ionization source (ESI). All the solvents were HPLC
grade. Mass spectral (MS) data were obtained using a LC/MSD VL
system with a 0.4 mL/min ﬂow rate using a binary solvent system of
95:5 methanol/water. UV detection was monitored at 254 nm. Mass
spectra were acquired in positive or negative mode scanning over the
mass range of 100−1500. The following ion source parameters were
used: drying gas ﬂow, 9 mL/min; nebulize pressure, 40 psig; drying gas
temperature, 350 °C. Microwave reactions were conducted using a
CEM Discover synthesis unit (CEM Corp., Matthews, NC). The
machine consists of a continuous focused microwave power delivery
system with operator-selectable power output from 0 to 300 W. The
temperature of the contents of the vessel was monitored using a
calibrated infrared temperature control mounted under the reaction
vessel. All experiments were performed using a stirring option whereby
the contents of the vessel are stirred by means of a rotating magnetic
plate located below the microwave cavity and a Teﬂon-coated
magnetic stir bar in the vessel.
Chromatographic analysis was performed using a Varian Polaris 5
C18-A column (150 mm × 4.6 mm, 5 μm particle size) at room
temperature. Analysis was carried out using gradient elution of a binary
solution; eluent A was ACN, while eluent B consisted of water. The
analysis started at 0% A for 3 min, then rapidly increased up to 98% in
12 min, and ﬁnally remained at 98% A until 18 min. The analysis was
performed at ﬂow rate of 0.8 mL min−1, and injection volume was 20
μL. Purity of compounds (as measured by peak area ratio) was >95%.
Chemistry. General Procedure for the Preparation of 2-(2,6-
Dihalophenyl)alkanoic Acids (5 and 6). Spectroscopic and
analytical data for compounds are in agreement with those reported
in the literature.
Example: 2-(2,6-Diﬂuorophenyl)propanoic Acid 640. A 1.6 M
solution of n-butyllithium in hexane (8.35 mL, 13.4 mmol) was added
dropwise in a round-bottomed ﬂask charged with a magnetic stirrer
and diisopropylamine (1.87 mL, 13.4 mmol), under anhydrous
conditions at −78 °C. After 15 min the mixture was diluted with
dry THF (16 mL) and stirred at −78 °C for further 30 min. A solution
of the appropriate acid (1.00 g, 5.8 mmol) in dry THF (14 mL) and
HMPA (1.52 mL, 8.7 mmol) were added dropwise, and the mixture
was warmed to −10 °C and stirred for 30 min. The orange solution
obtained was cooled to −78 °C, iodomethane (0.54 mL, 8.7 mmol)
was added, and the colorless solution obtained was gently warmed to
room temperature and stirred for 12 h. The mixture was then treated
with HCl 1 N (100 mL) and extracted with EtOAc (3 × 100 mL). The
combined organic phases were washed with HCl 1 N and brine, dried
over Na2SO4, ﬁltered, and concentrated under reduced pressure. The
crude residue was puriﬁed by ﬂash chromatography on silica gel,
eluting with 25% DCM/EtOAc to give pure compound 6 (isolated
yield 92%). 1H NMR (400 MHz, CDCl3) δ ppm 11.10 (bs, 1H) 7.32−
7.12 (m, 1H), 6.98−6.80 (m, 2H), 4.15 (q, J = 7.3 Hz, 2H), 1.50 (t, J =
16.1 Hz, 3H). LRMS (ESI) m/z = 184 [M − H]−.
2-(2,6-Dichlorophenyl)propanoic Acid 5. 1H NMR (400 MHz,
CDCl3) δ ppm 11.73 (bs, 1H) 7.32−7.28 (m, 1H), 7.13 (t, J = 8.0 Hz,
2H), 4.58 (q, J = 7.2 Hz, 1H), 1.54 (d, J = 7.2 Hz, 3H). LRMS (ESI)
m/z = 218 [M − H]−.40
Potassium 3-Ethoxy-2-methyl-3-oxopropanoate 8. A stirred
solution of diethyl methylmalonate (2.00 g, 11.5 mmol) in dry EtOH
(7 mL) under Ar atmosphere was cooled to 0 °C, and a solution of
KOH (0.64 g, 11.5 mmol) in dry EtOH (7 mL) was added dropwise.
The mixture was stirred at 0 °C for 30 min and then at room
temperature for 12 h. Solvent was evaporated, and the residue was
triturated with DCM. The white solid obtained was ﬁltered, washed
with hexane, and used in the next step without further puriﬁcation
(isolated yield 56%). 1H NMR (400 MHz D2O) δ ppm 4.11 (q, J = 7.1
Hz, 2H), 3.29 (q, J = 7.2 Hz, 1H), 1.24 (d, J = 7.2 Hz, 3H), 1.19 (t, J =
7.1 Hz, 3H).
General Procedure for the Preparation of Ethyl 4-(2,6-
Dihalophenyl)-2-methyl-3-oxoalkanoates (9−11). Example: 4-
(2,6-Diﬂuorophenyl)-2-methyl-3-oxopentanoate 11. To stirred
solution of 8 (1.59 g, 8.6 mmol) in dry CH3CN (20 mL) under argon
atmosphere triethylamine (1.66 mL, 12.0 mmol) and magnesium
chloride (0.85 g, 8.9 mmol) were added. The mixture was stirred at
room temperature for 1 h, and then a solution of 6 (0.51 g, 2.8 mmol)
and carbonyldiimidazole (0.50 g, 3.0 mmol) in dry CH3CN (15 mL)
was added dropwise. The mixture was stirred at room temperature for
12 h, then reﬂuxed for 2 h. After cooling, the mixture was gently
treated with HCl 3 N (20 mL) and the layers were separated. The
organic phase was washed with brine and a saturated solution of
NaHCO3 (3 × 20 mL). The organic solution was dried over Na2SO4,
ﬁltered, and concentrated under reduce pressure. The crude residue
was puriﬁed by ﬂash chromatography on silica gel, eluting with 10%
EtOAc/Hex to give pure compound 11 (isolated yield 61%). 1H NMR
(400 MHz, CDCl3) δ ppm 7.22−7.19 (m, 1H), 6.90−6.84 (m, 2H),
4.15 (dq, J = 7.2 Hz, 2H), 4.08−4.05 (m, 1H), 3.47−3.38 (m, 1H)
1.38 (t, J = 17.6 Hz, 3H), 1.29−1.22 (m, 6H). 13C NMR (100 MHz,
CDCl3) δ ppm 203.67, 170.13, 162.24, 129.21, 11.80, 111.69, 111.55,
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111.43, 61.16, 49.94, 46.04, 41.40, 14.76, 13.61, 12.7. LRMS (ESI) m/z
= 293 [M + H]+.
Ethyl 4-(2,6-Dichlorophenyl)-2-methyl-3-oxobutanoate 9.
1H NMR (400 MHz, CDCl3) δ ppm 7.29 (d, J = 8.0 Hz, 2H),
7.11−7.09(m, 1H), 4.30 (s, 2H), 4.20 (q, J = 7.2 Hz, 2H), 3.68 (q, J =
7.4 Hz, 1H), 1.41(d, J = 7.1 Hz, 3H), 1.29 (t, 3H). LRMS (ESI) m/z =
290 [M + H]+.
Ethyl 4-(2,6-Dichlorophenyl)-2-methyl-3-oxopentanoate 10.
1H NMR (400 MHz, CDCl3) δ ppm 7.33(d, J = 8.0 Hz, 2H), 7.20−
7.15 (m, 2H), 4.61 (q, J = 7.2 Hz, 1H), 4.09 (q, J = 6.2 Hz, 2H), 3.45
(q, J = 5.2 Hz, 1H), 1.45 (d, J = 7.2 Hz, 3H), 1.29 (d, J = 5.2 Hz, 3H),
1.22 (t, J = 6.2 Hz, 3H). LRMS (ESI) m/z = 304 [M + H]+, 325 [M +
Na]+.
General Procedure for the Preparation of 6-[1-(2,6-
Dihalophenyl)ethyl]-2-thioxo-2,3-dihydropyrimidin-4(1H)-
ones (12, 13, and 14). Example: 6-(1-(2,6-Diﬂuorophenyl)-
ethyl)-5-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 14.
To a stirred solution of sodium metal (0.06 g, 2.7 mmol) in dry
EtOH (5 mL) under Ar atmosphere thiourea (0.15 g, 1.9 mmol) was
added, and the mixture was stirred at room temperature until complete
dissolution. A solution of 11 (0.40 g, 1.3 mmol) in dry EtOH (15 mL)
was added dropwise, and the mixture was stirred at reﬂux for 12 h.
Solvent was evaporated and the residue treated with H2O and
neutralized with AcOH 0.5 N. The aqueous phase was extracted with
EtOAc (3 × 30 mL), dried over Na2SO4, ﬁltered, and concentrated
under reduced pressure. The crude residue was recrystallized from
EtOH to give compound 14 as a white solid (isolated yield 65%). 1H
NMR (400 MHz DMSO) δ ppm 11.59 (s, 1H), 7.46−7.29 (m, 1H),
7.08 (t, J = 8.6 Hz, 2H), 4.47 (q, J = 7.3 Hz, 1H), 1.61 (d, J = 7.3 Hz,
3H), 1.55 (s, 3H). LRMS (ESI) m/z = 305 [M + Na]+, 283 [M + H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-2-mercaptopyrimidin-4(3H)-
one 12. 1H NMR (400 MHz DMSO) δ ppm 9.44 (bs, 1H), 8.40 (bs,
1H), 7.45−7.25 (m, 3H), 4.18 (s, 1H), 2.09 (s, 3H). LRMS (ESI) m/z
= 302 [M + H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-2-mercapto-5-methylpyri-
midin-4(3H)-one 13. 1H NMR (400 MHz DMSO) δ ppm 12.50 (s,
1H), 10.99 (s, 1H), 7.48−7.43 (m, 2H), 7.31 (t, J = 8.0, Hz, 1H),
4.35−4.76 (m, 1H), 1.56 (d, J = 7.6 Hz, 3H), 1.36 (s, 3H). LRMS
(ESI) m/z = 315 [M + H]+.
General Procedure for the Preparation of 6-[1-(2,6-
Dihalophenyl)ethyl]-2-(methylthio)pyrimidin-4(3H)-ones (14−
17). Example: 6-(1-(2,6-Diﬂuorophenyl)ethyl)-5-methyl-2-
(methylthio)pyrimidin-4(3H)-one 17. To a stirred solution of
KOH (0.01 g, 0.16 mmol) in EtOH (2 mL) 14 (0.05 g, 0.16 mmol)
was added, and the mixture was stirred at room temperature until
complete dissolution. Iodomethane (0.01 mL, 0.16 mmol) was added
dropwise, and the mixture was stirred at room temperature for 1 h.
Solvent was evaporated and the residue dissolved in EtOAc (20 mL)
and washed with H2O (2 × 15 mL). The organic phase was dried over
Na2SO4, ﬁltered, and concentrated under reduced pressure. The crude
residue was puriﬁed by ﬂash chromatography on silica gel, eluting with
40% EtOAc/Hex to give pure compound 17 (isolated yield 95%). 1H
NMR (400 MHz DMSO) δ ppm 7.36−7.23 (m, 1H), 7.00 (m, 2H),
4.52 (q, J = 7.1 Hz, 1H), 2.36 (s, 3H), 1.82 (s, 3H), 1.56 (d, J = 7.1
Hz, 3H). LRMS (ESI) m/z = 319 [M + Na]+, 297 [M + H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methylthio)-
pyrimidin-4(3H)-one 15. Yield 94%, white solid. 1H NMR (400
MHz, CDCl3) δ ppm 7.24 (d, J = 8.0 Hz, 2H), 7.07 (t, J = 8.0 Hz,
1H), 4.92−4.87 (m, 1H), 2.59 (s, 3H), 1.65 (s, 3H), 1.63 (s, 3H).
LRMS (ESI) m/z = 329 [M + H]+.
6-(2,6-Dichlorobenzyl)-5-methyl-2-(methylthio)pyrimidin-
4(3H)-one 16. Yield 98%, white solid. 1H NMR (400 MHz, CDCl3) δ
ppm 7.30−7.10 (m, 3H), 4.22 (s, 2H), 2.17 (s, 3H), 2.15 (s, 3H).
LRMS (ESI) m/z = 316 [M + H]+.
General Procedure for the Preparation of 6-(1-(2,6-
Dihalophenyl)ethyl)-5-methyl-2-(methylsulfonyl)pyrimidin-
4(3H)-ones (18−20). Example: 6-(1-(2,6-Diﬂuorophenyl)ethyl)-
5-methyl-2-(methylsulfonyl)pyrimidin-4(3H)-one 20. To a
stirred solution of 17 (0.03 g, 0.10 mmol) in dry DCM (5 mL) at 0
°C, 3-chloroperbenzoic acid (0.05 g, 0.25 mmol) was added, and the
mixture was stirred at 0 °C for 1 h and then at room temperature for
12 h. The reaction was quenched with a saturated solution of
NaHCO3 (5 mL) and extracted with EtOAc (3 × 10 mL). The organic
phase was dried over Na2SO4, ﬁltered, and concentrated under
reduced pressure. The crude residue was puriﬁed by ﬂash
chromatography on silica gel, eluting with 2% MeOH/DCM to give
pure compound 20 (isolated yield 63%). 1H NMR (400 MHz, CDCl3)
δ ppm 7.23−7.10 (m, 1H), 6.83 (t, J = 8.4 Hz, 2H), 4.68 (q, J = 7.1
Hz, 1H), 3.29 (s, 3H), 2.09 (s, 3H), 1.69 (d, J = 7.1 Hz, 3H). LRMS
(ESI) m/z = 351 [M + Na]+, 329 [M + H]+.
6-(2,6-Dichlorobenzyl)-5-methyl-2-(methylsulfonyl)-
pyrimidin-4(3H)-one 18. Yield 63%, white solid. 1H NMR (400
MHz, CDCl3) δ ppm 7.30−7.10 (m, 3H), 4.22 (s, 2H), 2.17 (s, 3H),
2.15 (s, 3H). LRMS (ESI) m/z = 349 [M + H]+.
6 - ( 1 - ( 2 , 6 - D i c h l o r o p h e n y l ) e t h y l ) - 5 -m e t h y l - 2 -
(methylsulfonyl)pyrimidin-4(3H)-one 19. Yield 65%, white solid.
1H NMR (400 MHz, CDCl3) δ ppm 7.25(d, J = 8.0 Hz, 2H), 7.10 (t, J
= 8.0 Hz, 1H), 5.10 (q, J = 6.8 Hz, 1H), 3.30 (s, 3H), 1.73 (s, 3H),
1.69 (d, J = 6.8 Hz, 3H). LRMS (ESI) m/z = 362 [M + H]+.
tert-Butyl Piperazine-1-carboxylate (26b). Piperazine (100 mg,
1.61 mmol) and di-tert-butyl dicarbonate [(Boc)2O] (386 mg, 1.71
mmol) were suspended in MeOH (2 mL) in a 10 mL glass vial
equipped with a small magnetic stirring bar. The mixture was
irradiated for 2 min at 100 °C using an irradiation power of 300 W.
The reaction was monitored using TLC. After that time, cold water
was added (10 mL), and the reaction mixture was extracted with
EtOAc (3 × 5 mL). The organic phase was washed with brine, dried
over Na2SO4, ﬁltered, and concentrated under reduced pressure. The
resulting residue was puriﬁed by ﬂash chromatography (MeOH/
EtOAc 1:5). Yield 86%, white solid. 1H NMR (400 MHz, CDCl3) δ
(ppm) 3.35−3.33 (m, 4H), 2.77−2.75 (m, 4H), 2.03 (bs, 1H), 1.41 (s,
9H). LRMS (ESI) m/z: 187 [M + H]+.
General Procedure for the Preparation of Aminobenzalde-
hydes (21b−d). Example: tert-Butyl 4-(4-Formylphenyl)-
piperazine-1-carboxylate (21b). 4-Fluorobenzaldehyde (266 mg,
2.14 mmol), tert-butyl 4-(4-formylphenyl)piperazine-1-carboxylate
(400 mg, 2.14 mmol, K2CO3, 296 mg, 4.28 mmol) were stirred in
dry DMF at 130 °C under nitrogen atmosphere. After 12 h, the
reaction was quenched by addition of water. The resulting mixture was
extracted with EtOAc (3 × 25 mL), washed with brine, and dried over
anhydrous Na2SO4. The resulting residue was puriﬁed by ﬂash
chromatography (PE/EtOAc 4:1). Yield 65%, white solid. 1H NMR
(400 MHz, CDCl3) δ (ppm) 9.75 (s, 1H), 7.73 (d, J = 8.1 Hz, 2H),
6.87 (d, J = 8.1 Hz, 2H), 3.57−3.55 (m, 4H), 3.37−3.34 (m, 4H), 1.46
(s, 9H). LRMS (ESI) m/z: 291 [M + H]+.
4-Morpholinobenzaldehyde (21c). Yield 99%, yellow solid. 1H
NMR (400 MHz, CDCl3) δ (ppm) 9.79 (s, 1H), 7.76 (d, J = 8.0 Hz,
2H), 6.91 (d, J = 8.0 Hz, 2H), 3.84−3.82 (m, 4H), 3.33−3.31 (m,
4H). LRMS (ESI) m/z: 192 [M + H]+.
4-(4-Methylpiperazin-1-yl)benzaldehyde (21d). Yield 95%,
yellow solid. 1H NMR (400 MHz, CDCl3) δ (ppm) 9.76 (s, 1H),
7.72 (d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.0 Hz, 2H), 3.41−3.39 (m, 4H),
2.55−2.53 (m, 4H), 2.34 (s, 3H). LRMS (ESI) m/z: 205 [M + H]+.
General Procedure for the Preparation of 1-(Aralkyl)-N-
methylmethanamines (22b−g). Example: 1-(1H-Indazol-3-yl)-
N-methylmethanamine 22g. A 40% aqueous solution of methyl-
amine (0.16 mL, 2.05 mmol) was diluted with MeOH (8 mL). 1H-
Indazole-3-carboxaldehyde (0.10 g, 0.69 mmol) and NaHCO3 (0.03 g,
0.82 mmol) were added. The mixture was stirred at reﬂux for 4 h.
Then it was cooled to 0 °C and NaBH4 (0.12 g, 1.37 mmol) was
added and the mixture was stirred at room temperature for 1 h. The
reaction was quenched with H2O (10 mL) and extracted with EtOAc
(3 × 5 mL). The organic phase was dried over Na2SO4, ﬁltered, and
concentrated under reduced pressure. The crude residue was puriﬁed
by ﬂash chromatography on silica gel, eluting with a 0.5/1/9 mixture
of TEA/MeOH/DCM to give pure compound 22g (isolated yield
52%). 1H NMR (400 MHz, CDCl3) δ ppm 7.68 (d, J = 8.0 Hz, 1H),
7.33 (d, J = 8.3 Hz, 1H), 7.24 (t, J = 7.4 Hz, 1H), 7.04 (t, J = 7.3 Hz,
1H), 4.15 (s, 2H), 2.47 (s, 3H). LRMS (ESI) m/z = 162 [M + H]+.
tert-Butyl 4-(4-((Methylamino)methyl)phenyl)piperazine-1-
carboxylate (22b). Yield 90%, foam. 1H NMR (400 MHz, CDCl3)
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δ (ppm) 7.23 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 8.0 Hz, 2H), 4.80 (s,
1H), 3.73 (s, 2H), 3.56−3.54 (m, 4H), 3.11−3.09 (m, 4H), 2.42 (s,
3H), 1.47 (s, 9H). LRMS (ESI) m/z: 306 [M + H]+.
N-Methyl-1-(4-morpholinophenyl)methanamine (22c). Yield
95%, light yellow oil. 1H NMR (400 MHz, CDCl3) δ (ppm) 9.79 (s,
1H), 7.11 (d, J = 8.3 Hz, 2H), 6.75 (d, J = 8.3 Hz, 2H), 3.86−3.84 (m,
4H), 3.55 (s, 2H), 3.14−3.12 (m, 4H), 2.29 (s, 3H). LRMS (ESI) m/
z: 207 [M + H]+.
N -Methy l -1 - (4 - (4 -methy lp iperaz in -1 -y l )pheny l ) -
methanamine (22d). Yield 70%, yellow solid. 1H NMR (400 MHz,
CDCl3) δ (ppm) 7.10 (d, J = 8.0 Hz, 2H), 6.78 (d, J = 8.0 Hz, 2H),
3.54 (s, 2H), 3.09−3.07 (m, 4H), 2.46−2.44 (m, 4H), 2.34 (s, 3H).
LRMS (ESI) m/z: 220 [M + H]+.
(4-Methoxyphenyl)-N-methylmethanamine (22e). Yield 97%,
colorless oil. 1H NMR (400 MHz, CDCl3) δ (ppm) 7.13−7.11 (d, 2H,
J = 8.3 Hz), 6.77−6.75 (d, 2H, J = 8.3 Hz), 3.67 (s, 3H), 3.57 (s, 2H),
2.32 (s, 3H). LRMS (ESI) m/z: 152 [M + H]+.
N-Methyl-1-(4-nitrophenyl)methanamine (22f). Yield 95%,
orange solid. 1H NMR (400 MHz, CDCl3) δ (ppm) 8.17 (d, J =
8.6 Hz, 2H,), 7.49 (d, J = 8.6 Hz, 2H), 3.85 (s, 2H), 2.46 (s, 3H).
LRMS (ESI) m/z: 167 [M + H]+.
General Procedure for the Preparation of 2-(((1H-Indazol-3-
yl)methyl)(methyl)amino)-6-(1-(2,6-diﬂuorophenyl)ethyl)-5-
methylpyrimidin-4(3H)-ones. Example: 2-(((1H-Indazol-3-yl)-
methyl)(methyl)amino)-6-(1-(2,6-diﬂuorophenyl)ethyl)-5-
methylpyrimidin-4(3H)-one 25g. To stirred solution of 19 (0.03 g,
0.17 mmol) in dry toluene (5 mL) 22g (0.02 g, 0.06 mmol) was
added, and the mixture was stirred at reﬂux for 48 h. After cooling, the
mixture was diluted with MeOH and evaporated under reduced
pressure. The crude residue was puriﬁed by ﬂash chromatography on
silica gel, eluting with 5% MeOH/DCM to give pure compound 25g
(isolated yield 60%). 1H NMR (400 MHz, CDCl3) δ ppm 7.47 (dd, J
= 7.8, 5.8 Hz, 2H), 7.41−7.30 (m, 1H), 7.12−6.96 (m, 2H), 6.75 (t, J
= 8.3 Hz, 2H), 5.21 (d, J = 15.3 Hz, 1H CH-N), 4.96 (d, J = 15.3 Hz,
1H CH-N), 4.58 (q, J = 7.1 Hz, 1H), 3.05 (s, 3H), 1.93 (s, 3H), 1.65
(d, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 165.97,
165.52, 151.45, 142.43, 127.69, 126.97, 121.37, 120.88, 120.32, 111.37,
111.13, 109.95, 106.16, 45.13, 34.28, 17.60, 9.35, 5.45. LRMS (ESI)
m/z = 432 [M + Na]+, 410 [M + H]+.
6-(2,6-Dichlorobenzyl)-2-((4-methoxybenzyl)(methyl)-
amino)-5-methylpyrimidin-4(3H)-one (23e). The residue was
crystallized from EtOH. Yield 57%. White solid. 1H NMR (400
MHz, CDCl3) δ ppm 9.48 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 7.04 (t, J
=7.8 Hz, 1H), 6.88 (d, J = 8.0 Hz, 2H), 6.72−6.70 (m, 2H), 4.35 (s,
2H), 4.17 (s, 2H), 3.77 (s, 3H), 2.86 (s, 3H), 2.08 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ ppm 158.72, 135.90, 135.73, 129.91, 129.67,
128.98, 128.19, 113.84, 55.32, 50.99, 35.89, 34.24, 16.21, 10.08. LRMS
(ESI) m/z = 419 [M + H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-2-((4-methoxybenzyl)-
(methyl)amino)-5-methylpyrimidin-4(3H)-one (24e). The resi-
due was puriﬁed by ﬂash chromatography (DCM/MeOH 99:1). Yield
57%. White solid. 1H NMR (400 MHz, CDCl3) δ ppm 11.48 (s, 1H),
7.24 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 7.08−7.05 (m, 1H),
6.83 (d, J = 8.0 Hz, 2H), 6.92 (q, J = 7.3 Hz, 1H), 4.81 (m, 1H), 4.63
(m, 1H), 3.78 (s, 1H), 3.06 (s, 3H), 1.58 (d, J = 7.2 Hz, 3H), 3.06 (s,
3H), 1.58 (s, 3H), 1.51 (s, 3H). 13C NMR (100 MHz, CDCl3) δ
ppm158.72, 135.90, 135.73, 129.91, 129.67, 128.98, 113.84, 55.32,
50.99, 35.89, 34.24, 16.21, 15.68, 10.08. LRMS (ESI) m/z = 433 [M +
H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methyl(4-
morpholinobenzyl)amino)pyrimidin-4(3H)-one (24c). The resi-
due was puriﬁed by ﬂash chromatography (DCM/MeOH 95:5). Yield
62%, white solid. 1H NMR (400 MHz, CDCl3) δ ppm 7.27−7.02 (m
3H), 7.20−7.18 (d, J = 8.0 Hz, 2H), 6.98−6.96 (J = 8.0 Hz, 2H),
4.84−4.78 (q, J = 8.0 Hz, 1H), 4.94−4.59 (m, 2H), 3.85 (t, J = 4.0 Hz,
4H), 3.14 (t, J = 4.0 Hz, 4H), 3.06 (s, 3H), 1.55 (d, J = 7.1 Hz, 3H),
1.51 (s, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 161.5, 152.3, 150.4,
147.9, 141.0, 134.4, 128.8, 127.7, 126.8, 125.9, 122.7, 112.7, 66.3, 53.3,
52.3, 33.4, 18.1, 9.7. LRMS (ESI) m/z = 509 [M + Na]+, 487 [M +
H]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methyl(4-
morpholinobenzyl)amino)pyrimidin-4(3H)-one (23c). The resi-
due was puriﬁed by ﬂash chromatography (DCM/MeOH 99:1). Yield
65%. White solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.59 (s, 1H),
7.23 (d, J = 8.0 Hz, 2H), 7.03 (t, J = 7.9 Hz, 1H), 6.88 (d, J = 8.0 Hz,
2H), 6.73 (d, J = 8.0 Hz, 2H), 4.34 (s, 2H), 4.16 (s, 2H), 3.84 (t, J =
4.0 Hz, 4H), 3.11 (t, J = 4.0 Hz, 4H), 2.89 (s, 3H), 2.04 (s, 3H). 13C
NMR (100 MHz, CDCl3) δ ppm 158.72, 145.90, 135.73, 129.91,
129.67, 128.98, 113.84, 71.45, 58.91, 55.32, 50.99, 35.89, 34.24, 16.21,
10.08. LRMS (ESI) m/z = 474 [M + H]+.
6-(2,6-Dichlorobenzyl)-5-methyl-2-(methyl(4-(4-methylpi-
perazin-1-yl)benzyl)amino)pyrimidin-4(3H)-one (23d). The res-
idue was puriﬁed by ﬂash chromatography (DCM/MeOH 99:1). Yield
85%. White solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.50 (bs 1H),
7.25(d, J = 8.0 Hz, 2H), 7.03(d, J = 8.0 Hz, 2H), 7.22−6.73 (m, 3H),
4.34 (s, 2H), 4.23 (s, 2H), 3.19−3.17 (t, J = 4.0 Hz, 4H), 2.83 (s, 3H),
2.58 (t, J = 4.0 Hz, 4H), 2.31 (s, 3H), 1.98 (s, 3H). 13C NMR (100
MHz, CDCl3) δ ppm 161.5, 152.3, 147.9, 145.8, 138.5, 135.7, 128.8,
127.5, 126.8, 125.9, 123.5, 57.2, 52.3, 52.2, 52.0, 46.6, 33.4, 20.1, 9.4.
LRMS (ESI) m/z = 486 [M + H]+, 508 [M + Na]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methyl(4-(4-
methylpiperazin-1-yl)benzyl)amino)pyrimidin-4(3H)-one
(24d). The residue was puriﬁed by ﬂash chromatography (DCM/
MeOH 95:5). Yield 60%. White solid. 1H NMR (400 MHz, CDCl3) δ
ppm 7.24−7.02 (m, 3H), 7.16 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 8.0 Hz,
2H), 4.91−4.57 (m, 2H), 4.83−4.80 (q, J =4.0 Hz, 1H), 3.21 (t, J = 4.0
Hz, 4H), 3.04 (s, 3H), 2.60 (t, J = 4.0 Hz, 4H), 2.36 (s, 3H), 1.58 (t, J
= 8.0 Hz, 3H), 1.51 (s, 3H). 13C NMR (100 MHz, CDCl3) δ ppm
166.0, 165.4, 151.3, 150.4, 139.9, 135.2, 129.2, 116.2, 115.8, 115.5,
106.4, 55.0, 49.3, 48.9, 48.6, 46.0, 34.4, 16.0, 9.3. LRMS (ESI) m/z =
500 [M + H]+, 522 [M + Na]+.
tert-Butyl 4-(4-(((4-(2,6-Dichlorobenzyl)-5-methyl-6-oxo-1,6-
dihydropyrimidin-2-yl)(methyl)amino)methyl)phenyl)-
piperazine-1-carboxylate (23b). The residue was puriﬁed by ﬂash
chromatography (DCM/MeOH 95:5). Yield 65%. White solid. 1H
NMR (400 MHz, CDCl3) δ ppm 10.56 (bs, 1H), 7.25−7.02 (m, 3H),
6.99−6.73 (m, 4H), 4.34 (s, 2H), 3.56−3.54 (m, 4H), 3.08−3.06 (m,
4H), 2.89 (s, 3H), 2.04 (s, 3H), 1.47 (s, 9H). 13C NMR (100 MHz,
CDCl3) δ ppm 165.5, 161.6, 154.7, 152.3, 151.5, 150.6, 136.4, 135.9,
129.2, 127.6, 116.4, 112.7, 106.2, 79.9, 51.8, 49.4, 36.1, 34.1, 8.4, 9.7,
9.4. LRMS (ESI) m/z = 573 [M + H]+.
6-(2,6-Dichlorobenzyl)-5-methyl-2-(methyl(4-(piperazin-1-
yl)benzyl)amino)pyrimidin-4(3H)-one 2,2,2-Triﬂuoroacetate
(23a). The residue was crystallized from ethanol. Yield 95%. White
solid. 1H NMR (400 MHz, CDCl3) δ ppm 10.42 (bs, 1H), 7.24−7.09
(m, 3H), 6.89−6.62 (m, 4H), 4.77 (s, 2H), 4.27 (s, 2H), 3.52−3.49
(m, 4H), 2.88−2.95 (m, 4H), 2.89 (s, 3H), 1.94 (s, 3H). 13C NMR
(100 MHz, CDCl3) δ ppm 165.0, 165.4, 150.9, 150.2, 140.2, 136.1,
128.6, 115.7, 115.5, 106.4, 55.0, 49.3, 48.9, 48.6, 46.4, 9.1. LRMS (ESI)
m/z = 472 [M + H]+, 495 [M + Na]+.
tert-Butyl 4-(4-(((4-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-
6-oxo-1,6-dihydropyrimidin-2-yl)(methyl)amino)methyl)-
phenyl)piperazine-1-carboxylate (24b). The residue was puriﬁed
by ﬂash chromatography (DCM/MeOH 95:5). Yield 65%. White
solid. 1H NMR (400 MHz, CDCl3) δ ppm 7.36−7.31 (m, 3H), 7.15
(d, J = 8.0 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H),), 5.07 (q, J = 8.0 Hz,
1H), 4.96 (d, J = 15.1 Hz, 1H CH-N), 4.59 (d, J = 15.1 Hz, 1H CH-
N), 3.52−3.50 (m, 4H), 3.04−3.02 (m, 4H), 2.89 (s, 3H), 1.89 (s,
3H), 1.56 (d, J = 8.0 Hz, 3H), 1.47 (s, 9H) ppm. 13C NMR (100 MHz,
CDCl3) δ ppm 165.5, 161.6, 154.7, 152.3, 151.5, 150.6, 136.4, 135.9,
129.2, 127.6, 116.4, 112.7, 106.2, 79.9, 51.8, 49.4, 36.1, 34.1, 8.4, 9.7,
9.4. 164.8, 160.6, 153.1, 152.7, 151.9, 151.6, 137.4, 135.9, 129.2, 128.6,
117.3, 113.7, 107.1, 80.0, 51.6, 48.1, 36.0, 34.3, 18.2, 8.6, 9.9, 9.3.
LRMS (ESI) m/z = 586 [M + H]+, 608 [M + Na]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methyl(4-(pi-
perazin-1-yl)benzyl)amino)pyrimidin-4(3H)-one 2,2,2-Triﬂuor-
oacetate (24a). The residue was crystallized from ethanol. Yield 95%.
White solid. 1H NMR (400 MHz, CDCl3) δ ppm
1H NMR (400
MHz, CDCl3) δ ppm 7.23−7.01 (m, 3H), 7.15 (d, J = 8.0 Hz, 2H),
6.82 (d, J = 8.0 Hz, 2H),), 4.91−4.57 (m, 2H), 4.82 (q, J = 8.0 Hz,
1H), 3.52−3.50 (m, 4H), 3.04−3.02 (m, 4H), 2.89 (s, 3H), 1.89 (s,
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3H), 1.56 (d, J = 8.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ
ppm 165.5, 161.6, 161.2, 152.3, 151.5, 150.6, 136.4, 135.9, 129.2,
127.6, 116.4, 112.7, 106.2, 51.8, 49.4, 36.1, 34.1, 8.4, 9.7, 9.4. 164.8,
160.6, 153.1, 152.7, 151.9, 151.6, 137.4, 135.9, 129.2, 128.6, 117.3,
115.9, 113.7, 107.1, 80.0, 51.6, 48.1, 36.0, 18.2, 8.6, 9.9, 9.3. LRMS
(ESI) m/z = 486 [M + H]+, 508 [M + Na]+.
6-(1-(2,6-Dichlorophenyl)ethyl)-5-methyl-2-(methyl(4-
nitrobenzyl)amino)pyrimidin-4(3H)-one (24f). The residue was
puriﬁed by ﬂash chromatography (DCM/MeOH 95:5). Yield 40%.
White solid. 1H NMR (400 MHz, CDCl3) δ ppm 8.16 (d, J = 8.0 Hz,
2H), 7.40 (d, J = 8.0 Hz, 2H), 7.24−7.20 (m, 2H), 7.04 (t, J = 8.0 Hz,
1H), 5.12−4.78 (m, 1 H), 3.43 (s, 2H), 3.14 (s, 3H), 1.55 (s, 3H),
1.51−1.48 (m, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 162.3,
156.6, 152.1, 146.2, 142.5, 141.1, 135.5, 129.0, 127.9, 127.0, 124.2,
123.0, 55.1, 36.5, 35.0, 21.1, 14.2. LRMS (ESI) m/z = 448 [M + H]+.
6-(1-(2,6-Diﬂuorophenyl)ethyl)-5-methyl-2-(methyl(4-
nitrobenzyl)amino)pyrimidin-4(3H)-one (25f). The residue was
puriﬁed by ﬂash chromatography (DCM/MeOH 95:5). Yield 64%.
White solid. 1H NMR (400 MHz, CDCl3) δ ppm 8.10 (d, J =8.0 Hz,
2H), 7.31−7.26 (m, 2H), 7.09−7.03 (m, 1H), 6.73 (t, J = 8.0 Hz, 1H),
5.09 (d, J = 15.3 Hz, 1H CH-N), 4.62 (d, J = 15.3 Hz, 1H CH-N),
4.53 (q, J = 8.0 Hz, 3H), 3.09 (s, 3H), 1.89 (s, 3H), 1.56 (d, J = 7.1
Hz, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 163.38, 163.38, 161.49,
155.86, 147.59, 144.57, 130.19, 128.29, 128.29, 123.78, 123.78, 122.27,
113.52, 112.06, 112.06, 57.42, 38.24, 38.01, 21.95, 13.66. LRMS (ESI)
m/z = 400 [M + H]+.
6-(1-(2,6-Diﬂuorophenyl)ethyl)-2-((4-methoxybenzyl)-
(methyl)amino)-5-methylpyrimidin-4(3H)-one (25e). The resi-
due was puriﬁed by ﬂash chromatography (DCM/MeOH 95:5). Yield
60%. White solid. 1H NMR (400 MHz, CDCl3) δ ppm 7.10−7.08 (m,
3H), 6.79−6.75 (m, 4H), 6.82 (d, J = 8.0 Hz, 2H), 4.86 (d, J = 15.3
Hz, 1H CH-N), 4.55−4−52 (m, 3H), 2,76 (s, 3H), 3.00 (s, 3H), 1.86
(s, 3H), 1.62 (d, J = 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ
ppm 163.38, 163.38, 161.49, 159.18, 155.86, 130.19, 128.91, 128.91,
128.00, 122.27, 113.54, 113.54, 113.52, 112.06, 112.06, 57.42, 56.04,
38.24, 38.01, 21.95, 13.66. LRMS (ESI) m/z = 400 [M + H]+.
Biology. Cells. The JC53-BL cell line, also known as the TZM-bl
cell line (NIH AIDS Research and Reference Reagent Program,
Germantown, USA), was used for the evaluation of anti-HIV-1 activity
of the N-DABOs. TZM-bl cells were cultured in Dulbecco’s minimum
essential medium (DMEM) (Lonza) containing 10% heat-inactivated
FBS and 50 μg of gentamycin/mL at 37 °C in a humidiﬁed 5% CO2,
95% air environment. Twice a week the cells were treated with 0.25%
trypsin−1 mM EDTA (Lonza) for 10 min. The resulting cell
suspension was washed with an equivalent amount of TZM-bl medium
and subsequently seeded in a T75 culture ﬂask (Greiner Bio-One,
Germany) at 106 cells in 20 mL of medium.
Antiviral Activity Assay. The antiviral activity of the newly designed
compounds was measured by preincubating 10 000 TZM-bl cells (at
105 cells/mL in culture medium supplemented with 30 μg/mL DEAE
dextran) in a 96-well plates for 30 min at 37 °C, 5% CO2 in the
presence or absence of serial dilutions of the respective compound.
Subsequently, 200 TCID50 of HIV-1 WT or mutant virus was added to
each well and cultures were incubated for 48 h before quantifying
luciferase activity, using a TriStar LB941 luminometer (Berthold
Technologies GmbH & Co., KG, Bad Wildbad, Germany). Each
condition was evaluated in triplicate wells and in at least two
independent experiments. The antiviral activity of the compound was
expressed as the percentage of viral inhibition compared to the
untreated controls and subsequently plotted against the compound
concentration. Nonlinear regression analysis was used to calculate the
50% eﬀective concentration (EC50) based on at least two independent
measurements and using GraphPad Prism, version 5.03, for Windows
(GraphPad Software, San Diego, CA, USA). The antiviral activity of
the 25e gel formulation was tested by the same procedure and in
comparison with free 25e in solution and the gel without compound
(blank).
Antiviral Activity by Using a Transwell Assay. To avoid the
antiviral eﬀect of β-cyclodextrins and the toxic eﬀect on monolayers of
highly concentrated gels (toxicity was observed with the original
preparation at 5% concentration), 25e gel was reformulated without
these additives and antiviral activity was investigated with a Transwell
experiment. TZM-bl cells were plated at 4 × 104 cells/well into each
Transwell apical chamber of a 24-well plate (pore size 3 μm and
diameter 6.5 mm, Corning Costar). The insert was placed in the
bottom plate, which contains cell culture medium and cultured
overnight. NL4.3 HIV virus was titrated as follows: medium was
removed from all wells, and 100 μL of blank gel was added to all the
apical chambers. A serial dilution of NL4.3 stock virus was made and
100 μL was added in triplicate to the top chamber, while culture
medium was added in the bottom compartment. After 72 h luciferase
activity was quantiﬁed as above.
For eﬃcacy testing, 60 TCID50 of virus was added to each apical
well in the presence of 100 μL of 25e gel, tenofovir gel, or blank gel at
the ﬁnal drug concentrations of 5000, 500, 50, 5, and 0.5 nM. In all
apical wells, gels were used at 50% concentration directly on
monolayers, but cells were exposed to the culture medium present
in the bottom plate. Inhibition was determined as previously based on
deviations from blank gel.
Reverse Transcriptase Activity Assay. Chemicals. [3H]dTTP (40
Ci/mmol) was from PerkinElmer, and unlabeled dTTP was from
Promega. PerkinElmer was the supplier of the GF/C ﬁlters. All other
reagents were of analytical grade and purchased from Merck or Sigma-
Aldrich.
Polymerase Assay. The homopolymer poly(rA) (Pharmacia) was
mixed at weight ratios in nucleotides of 10:1 to the oligomer
oligo(dT)12−18 (Pharmacia) in 20 mM Tris-HCl (pH 8.0)
containing 20 mM KCl and 1 mM EDTA, heated at 65 °C for 5
min, and then slowly cooled at room temperature. The coexpression
vectors pUC12N/p66(His)/p51 with the wild-type or mutant forms
of HIV-1 RT p66 were kindly provided by Dr. S. H. Hughes (NCI-
Frederick Cancer Research and Development Center). Proteins were
expressed in Escherichia coli and puriﬁed as described.40 RNA-
dependent DNA polymerase activity was assayed as follows: a ﬁnal
volume of 25 μL contained reaction buﬀer (50 mM Tris-HCl, pH 7.5,
1 mM DTT, 0.2 mg/mL BSA, 4% glycerol), 10 mM MgCl2, 0.5 μg of
poly(rA)/oligo(dT)10:1 (0.3 μM 3′-OH ends), 10 μM [3H]dTTP (1
Ci/mmol), and 2−4 nM RT. Reactions were incubated at 37 °C for 20
min. Ten microliter aliquots were then spotted on glass ﬁber ﬁlters
GF/C, which were immediately immersed in 5% ice-cold TCA. Filters
were washed twice in 5% ice-cold TCA and once in ethanol for 5 min
and dried. Acid-precipitable radioactivity was quantitated by
scintillation counting (Trilux Perkinelmer).
Inhibition Assays. Inhibition assays were performed under the
conditions described for the HIV-1 RT RNA-dependent DNA
polymerase activity assay. Incorporation of radioactive dTTP into
poly(rA)/oligo(dT) at diﬀerent substrate (nucleic acid or dTTP)
concentrations was monitored in the presence of increasing ﬁxed
amounts of inhibitor. Data were then plotted according to Line-
weaver−Burke and Dixon. For inhibition constant (Ki) determination,
an interval of inhibitor concentration between 0.2Ki and 5Ki was used.
WST-1 Cytotoxicity Assay. The water-soluble tetrazolium-1 (WST-
1) cell proliferation assay is a colorimetric assay for the measurement
of cell proliferation and viability. The assay is based on the cleavage of
the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) to a formazan dye by a
complex cellular mechanism. This bioreduction is largely dependent
on the glycolytic production of NAD(P)H in viable cells. Therefore,
the amount of formazan dye formed correlates directly to the number
of viable cells in the culture and can be quantiﬁed by measuring the
absorbance at 450 nm in a multiwell plate reader. The greater is the
number of viable cells, the greater is the amount of formazan dye
produced following the addition of WST-1. Cytotoxicity of each
compound was evaluated using this WST-1 viability assay, according to
the manufacturer’s instructions (Roche, Vilvoorde, Belgium). Brieﬂy,
10 000 TZM-bl cells were seeded in a 96-well plates and cultured for 2
days in the presence of a serial dilution of compound. After this 48 h
exposure, cell proliferation reagent, WST-1, was added and absorbance
at 450 nm was quantiﬁed after 90 min using a microplate reader
(BioRad, Tokio, Japan). Each compound was tested in three replicate
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wells and in at least two independent experiments. The percentage cell
viability, compared to untreated controls, was plotted against the
compound concentration, and nonlinear regression analysis was
performed using GraphPad Prism, version 5.02, for Windows
(GraphPad Software, San Diego, CA, USA) to calculate the 50%
cytotoxic concentration (CC50).
ADME Assay. Chemicals and Excipients. All solvents, L-α-
phosphatidylcholine, 2-hydroxypropyl-β-cyclodextrin (2-HP-βCD),
hydroxyethylcellulose (HEC), and propionic acid were from Sigma-
Aldrich Srl (Milan, Italy). Dodecane was purchased from Fluka (Milan,
Italy). Milli-Q quality water (Millipore, Milford, MA, USA) was used.
Hydrophobic ﬁlter plates (MultiScreen-IP, Clear Plates, 0.45 μm
diameter pore size), 96-well microplates, and 96-well UV-transparent
microplates were obtained from Millipore (Bedford, MA, USA).
Parallel Artiﬁcial Membrane Permeability Assay (PAMPA). Donor
solution (0.5 mM) was prepared by diluting 1 mM dimethylsulfoxide
(DMSO) compound stock solution using two buﬀers: phosphate
buﬀer (25 mM, pH 7.4) and acetate buﬀer (50 mM, pH 4.2). Filters
were coated with 5 μL of a 1% (w/v) dodecane solution of
phosphatidylcholine. Donor solution (150 μL) was added to each well
of the ﬁlter plate. To each well of the acceptor plate was added an
amount of 300 μL of solution (50% DMSO in phosphate buﬀer). All
compounds were tested in three diﬀerent plates on diﬀerent days. The
sandwich was incubated for 5 h at room temperature under gentle
shaking. After the incubation time, the plates were separated, and
samples were taken from both receiver and donor sides and analyzed
using LC with UV detection at 280 nm.
LC analysis was performed with a Varian Prostar HPLC system
(Varian Analytical Instruments, USA) equipped with a binary pump
with a manual injection valve and model Prostar 325 UV−vis detector.
Chromatographic separation was conducted using a Phenomenex
Kinetex C18-100A column (150 mm × 4.6 mm, 5 μm particle size) at
a ﬂow rate of 0.6 mL/min with a mobile phase composed of 60%
ACN/40% formic acid (0.1%) or 35% ACN/65% formic acid (0.1%)
for compounds 23f, 25e, 23c, 24c, 23d, 24d, respectively.
Permeability (Pe) was calculated according to the following
equation, from Reis et al.,42 in order to obtain eﬀective permeability
values in cm/s,
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VA is the volume in the acceptor well, VD is the volume in the donor
well (cm3), A is the “eﬀective area” of the membrane (cm2), CA(t) is
the compound concentration in acceptor well at time t, CD(t) is the
compound concentration in donor well at time t, and t is the
incubation time (s).
Water Solubility Assay. Each solid compound (1 mg) was added to
1 mL of phosphate buﬀer (25 mM, pH 7.4) or acetate buﬀer (50 mM,
pH 4.2). The samples were shaken in a shaker bath at room
temperature for 24−36 h. Each suspension was ﬁltered through a 0.45
μm nylon ﬁlter (Acrodisc), and the solubilized compound was
determined by LC−MS−MS assay. For each compound the
determination was performed in triplicate. For the quantiﬁcation the
following was used: an LC−MS system consisting of a Varian
apparatus (Varian Inc.) including a vacuum solvent degassing unit, two
pumps (212-LC), a triple quadrupole MSD (model 320-LC) mass
spectrometer with ES interface, and Varian MS Workstation System
Control, version 6.9 software. Chromatographic separation was
obtained using a Pursuit C18 column (50 mm × 2.0 mm) (Varian)
with 3 μm particle size and gradient elution, with eluent A being ACN
and eluent B consisting of an aqueous solution of formic acid (0.1%).
The analysis started with 0% of eluent A, which was linearly increased
up to 70% in 10 min, then slowly increased up to 98% up to 15 min.
The ﬂow rate was 0.3 mL/min, and injection volume was 5 μL. The
instrument operated in positive mode, and parameters were the
following: detector 1850 V, drying gas pressure 25.0 psi, desolvation
temperature 300.0 °C, nebulizing gas 40.0 psi, needle 5000 V, and
shield 600 V. Nitrogen was used as nebulizer gas and drying gas.
Collision induced dissociation was performed using argon as the
collision gas at a pressure of 1.8 mTorr in the collision cell. The
transitions as well as the capillary voltage and the collision energy used
for compound are summarized in Table 4.
Quantiﬁcation of the single compound was made by comparison
with apposite calibration curves realized with standard solutions in
methanol.
Solubility Assessment. The solubilizing capacity of formulation
media was measured in the presence of 50% w/w of 2-HP-β-CD.
Stock solution of compound 25e (DMSO) was added to obtain a
concentration of 20 μM in a ﬁnal volume of 1 mL (DMSO did not
exceed 2%). After sonication, the samples were shaken in a shaker bath
at room temperature for 24 h to reach equilibrium conditions. Each
pregel solution was analyzed before and after ﬁltration by a 0.45 μm
nylon ﬁlter (Acrodisc). The loaded compound was determined using
LC−UV−MS method already described for the permeability.
Molecular Modeling. Protein Preparation. The reverse tran-
scriptase three-dimensional coordinates were selected from the Protein
Data Bank (PDB entry code 1RT2)41 and was prepared by means of
Protein Preparation Wizard workﬂow implemented in the Maestro
suite.42 In particular, the inhibitor and the water molecules were
deleted, hydrogen atoms were added, and bond orders and charges
were assigned; the orientation of hydroxyl groups on Ser, Thr, and
Tyr, the side chains of Asn and Gln residues, and the protonation state
of His residues were optimized. Steric clashes were relieved by
performing a small number of minimization steps, not intended to
minimize the system completely. In our study, the minimization
(OPLS force ﬁeld) was stopped when the rmsd of the non-hydrogen
atoms reached 0.30 Å. The same procedure was applied to prepare the
RT protein in complex with the water molecule making a bridge
between the crystallized ligand TNK-651 and the amino acids Lys101
of chain A and Glu138 of chain B. In this case, the water molecule
1023 was kept in the system during the Protein Preparation Wizard
workﬂow. To prepare the input structure for Autodock calculations,
the RT structure was further manipulated by removing nonpolar
hydrogen atoms, while Kollman united-atom partial charges and
solvent parameter were added. Autogrid was then used to generate
grid maps.
Ligand Preparation. 168 S-DABOs/N-DABOs were collected from
previous work and were built with the Schrodinger Maestro 9.2
graphical interface.42 Compounds were then processed with the
Schrodinger LigPrep tool to generate separate ﬁles for all possible
enantiomers and protonation states at phisiological pH. OPLS_2005
was used as force ﬁeld. Ligands for Autodock were further reﬁned by
Table 4. Chromatographic and MS Parameters (Monitored
Transition, Collision Energy, Capillary Voltage, and
Retention Time tR) of the Selected Compounds
compd
transition
(m/z)
collision energy
(eV)
capillary voltage
(V)
tR
(min)
23c 309.9 −17.5 10 12.9
176.0 −32.0
23d 309.8 −21.0 10 11.2
253.8 −36.5
24d 323.9 −25.0 38 11.6
288.0 −35.0
23f 261.8 −30.5 24 10.2
206.0 −45.0
25e 291.9 17.0 50 11.0
120.8 25.0
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deleting the nonpolar hydrogen atoms and adding Gasteiger atomic
charges.
Docking Simulation. Docking studies were performed within the
NNBP of RT using three software packages: Autodock,28 Gold,29 and
Glide.30,31 The reliability of the docking protocols was ﬁrst checked by
simulating the binding mode of known ligands for which the poses
have been experimentally determined (TNK-651, MKC-442, and
HEPT). The three docking algorithms were able to correctly predict
the binding modes of the reference compounds. With regard to the
Gold program, the ChemScore scoring function was found to be the
best one in terms of pose prediction (in comparison with GoldScore,
CHEMPLP, and ASP) and was thus used in the following calculations.
The genetic algorithm parameter settings were employed using the
search eﬃciency set at 100%, and 100 runs were carried out for each
ligand. Finally, results diﬀering less than 1 Å in ligand-all atom rmsd
were clustered together. For each inhibitor, the ﬁrst ranked solution
was selected for further analysis. The Lamarckian genetic algorithm
(LGA) was used in Autodock to explore the possible orientations/
conformations of the inhibitors in the binding site. For each
compound, the following protocol was applied: 50 independent
LGA runs, a population size of 150 individuals, and a maximum
number of 2 500 000 energy evaluations. Moving to the Glide
software, compounds were docked and scored using the Glide
Standard Precision (SP) mode.
Multiple Linear Regression. QSAR calculations were performed
using Canvas implemented in Maestro (version 9.5).42 The conformer
of each inhibitor was extracted from the complex with RT and
submitted to the calculation of both QikProp and 2D ﬁngerprint
descriptors. These calculated properties, together with the parameters
previously derived from docking studies with three diﬀerent software
as well as with the rescoring methods employed (MM-GBSA,
XSCORE), were used as dependent variables to generate multiple
linear regression (MLR) models, while enzymatic or cellular data were
in turn used as the independent variable (expressed as −log IC50 or
−log EC50). In the case of chiral compounds, the 3D energetic
parameters coming from docking studies were calculated as the
medium of the values obtained with all the possible diastereomeric
forms. Molecules together with the calculated descriptors were
imported in the cheminformatics package Canvas, and a MLR was
carried out. The Simulated Annealing algorithm of Canvas was applied
to descriptors to eﬃciently search the wide solution space and to
identify the best subsets of descriptors to build robust QSAR models.
The number of Monte Carlo steps was set to 1000.
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disciplinary approach for the identification of novel HIV-1 non-
nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPs.
ChemMedChem 2008, 3, 573−593.
(10) Botta, M.; Corelli, F.; Petricci, E.; Radi, M.; Maga, G.; Este,̀ J. A.;
Mai, A. WO/2007/043094, 2007.
(11) Radi, M.; Angeli, L.; Franchi, L.; Contemori, L.; Maga, G.;
Samuele, A.; Zanoli, S.; Armand-Ugon, M.; Gonzalez, E.; Llano, A.;
Este,́ J. A.; Botta, M. Towards novel S-DABOC inhibitors: synthesis,
biological investigation, and molecular modeling studies. Bioorg. Med.
Chem. Lett. 2008, 18, 5777−5780.
(12) Radi, M.; Maga, G.; Alongi, M.; Angeli, L.; Samuele, A.; Zanoli,
S.; Bellucci, L.; Tafi, A.; Casaluce, G.; Giorgi, G.; Armand-Ugon, M.;
Gonzalez, E.; Este,́ J. A.; Baltzinger, M.; Bec, G.; Dumas, P.; Ennifar,
E.; Botta, M. Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-
oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse
transcriptase inhibitors with high activity against clinically relevant
mutants. J. Med. Chem. 2009, 52, 840−851.
(13) Radi, M.; Pagano, M.; Franchi, L.; Castagnolo, D.; Schenone, S.;
Casaluce, G.; Zamperini, C.; Dreassi, E.; Maga, G.; Samuele, A.;
Gonzalo, E.; Clotet, B.; Este,́ J. A.; Botta, M. Synthesis, biological
activity, and ADME properties of novel S-DABOs/N-DABOs as HIV
reverse transcriptase inhibitors. ChemMedChem 2012, 7, 883−896.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01979
J. Med. Chem. 2016, 59, 2747−2759
2758
(14) Olsen, J. S.; Easterhoff, D.; Dewhurst, S. Advances in HIV
microbicide development. Future Med. Chem. 2011, 3, 2101−2116.
(15) Arien̈, K. K.; Venkatraj, M.; Michiels, J.; Joossens, J.; Vereecken,
K.; Van der Veken, P.; Abdellati, S.; Cuylaerts, V.; Crucitti, T.;
Heyndrickx, L.; Heeres, J.; Augustyns, K.; Lewi, P. J.; Vanham, G.
Diaryltriazine non-nucleoside reverse transcriptase inhibitors are
potent candidates for pre-exposure prophylaxis in the prevention of
sexual HIV transmission. J. Antimicrob. Chemother. 2013, 68, 2038−
2047.
(16) Fletcher, P.; Harman, S.; Azijn, H.; Armanasco, N.; Manlow, P.;
Perumal, D.; de Bet́hune, M. P.; Nuttall, J.; Romano, J.; Shattock, R.
Inhibition of human immunodeficiency virus type 1 infection by the
candidate microbicide dapivirine, a nonnucleoside reverse transcriptase
inhibitor. Antimicrob. Agents Chemother. 2009, 53, 487−495.
(17) Fernańdez-Romero, J. A.; Thorn, M.; Turville, S. G.; Titchen,
K.; Sudol, K.; Li, J.; Miller, T.; Robbiani, M.; Maguire, R. A.; Buckheit,
R. W.; Hartman, T. L.; Phillips, D. M. Carrageenan/MIV-150 (PC-
815), a combination microbicide. Sex. Transm. Dis. 2007, 34, 9−14.
(18) Hossain, M. M.; Parniak, M. A. In vitro microbicidal activity of
the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781
against NNRTI-resistant human immunodeficiency virus type 1. J.
Virol. 2006, 80, 4440−4446.
(19) D’Cruz, O. J.; Uckun, F. M. Dawn of non-nucleoside inhibitor-
based anti-HIV microbicides. J. Antimicrob. Chemother. 2006, 57, 411−
423.
(20) Abdool Karim, Q.; Abdool Karim, S. S.; Frohlich, J. A.; Grobler,
A. C.; Baxter, C.; Mansoor, L. E.; Kharsany, A. B.; Sibeko, S.; Mlisana,
K. P.; Omar, Z.; Gengiah, T. N.; Maarschalk, S.; Arulappan, N.;
Mlotshwa, M.; Morris, L.; Taylor, D. CAPRISA 004 Trial Group.
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide,
for the prevention of HIV infection in women. Science 2010, 329,
1168−1174.
(21) Doncel, G. F.; Clark, M. R. Preclinical evaluation of anti-HIV
microbicide products: new models and biomarkers. Antiviral Res. 2010,
88 (Suppl. 1), S10−S18.
(22) Desai, M.; Iyer, G.; Dikshit, R. K. Antiretroviral drugs: critical
issues and recent advances. Indian J. Pharmacol. 2012, 44, 288−298.
(23) Vanpouille, C.; Arakelyan, A.; Margolis, L. Microbicides: still a
long road to success. Trends Microbiol. 2012, 20, 369−375.
(24) Pozzetto, B.; Delezay, O.; Brunon-Gagneux, A.; Hamzeh-
Cognasse, H.; Lucht, F.; Bourlet, T. Current and future microbicide
approaches aimed at preventing HIV infection in women. Expert Rev.
Expert Rev. Anti-Infect. Ther. 2012, 10, 167−183.
(25) Selhorst, P.; Vazquez, A. C.; Terrazas-Aranda, K.; Michiels, J.;
Vereecken, K.; Heyndrickx, L.; Weber, J.; Quiñones-Mateu, M. E.;
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